biostudies-literatureKolte DNHLBI NIH HHS934-944https://www.ebi.ac.uk/biostudies/studies/S-EPMC9330296biostudies-literatureUnknown7(9)<h4>Importance</h4>In patients with severe aortic stenosis and left ventricular ejection fraction (LVEF) less than 50%, early LVEF improvement after transcatheter aortic valve replacement (TAVR) is associated with improved 1-year mortality; however, its association with long-term clinical outcomes is not known.<h4>Objective</h4>To examine the association between early LVEF improvement after TAVR and 5-year outcomes.<h4>Design, setting, and participants</h4>This cohort study analyzed patients enrolled in the Placement of Aortic Transcatheter Valves (PARTNER) 1, 2, and S3 trials and registries between July 2007 and April 2015. High- and intermediate-risk patients with baseline LVEF less than 50% who underwent transfemoral TAVR were included in the current study. Data were analyzed from AugusJAMA cardiologyAssociation Between Early Left Ventricular Ejection Fraction Improvement After Transcatheter Aortic Valve Replacement and 5-Year Clinical Outcomes.PMC9330296K23 HL157612Vlahakes GJSmith CRBhardwaj BDaubert MAJaber WElmariah SGarcia SInglessis IKodali SMack MJPibarot PClavel MAPalacios IFThourani VHPasseri JJLindman BRLu MDouglas PSKolte DLeon MBCohen DJAlu MCfalseAssociation Between Early Left Ventricular Ejection Fraction Improvement After Transcatheter Aortic Valve Replacement and 5-Year Clinical Outcomes.<h4>Importance</h4>In patients with severe aortic stenosis and left ventricular ejection fraction (LVEF) less than 50%, early LVEF improvement after transcatheter aortic valve replacement (TAVR) is associated with improved 1-year mortality; however, its association with long-term clinical outcomes is not known.<h4>Objective</h4>To examine the association between early LVEF improvement after TAVR and 5-year outcomes.<h4>Design, setting, and participants</h4>This cohort study analyzed patients enrolled in the Placement of Aortic Transcatheter Valves (PARTNER) 1, 2, and S3 trials and registries between July 2007 and April 2015. High- and intermediate-risk patients with baseline LVEF less than 50% who underwent transfemoral TAVR were included in the current study. Data were analyzed from Augus2022-01-01T00:00:00Z2022 Sep2025-04-04T20:07:43.25Z2025-04-04T20:07:43.25ZS-EPMC93302963589504610.1001/jamacardio.2022.2222